Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

20131,904 citationsJournal Articlebronze Open Access

Authors

Robert J. Motzer · Memorial Sloan Kettering Cancer Center

Thomas E. Hutson · Texas Oncology

David Cella · Robert H. Lurie Comprehensive Cancer Center of Northwestern University

James A. Reeves · Florida Cancer Specialists & Research Institute

Robert D. Hawkins · The Christie NHS Foundation Trust

Jun Guo · Peking University

Paul Nathan

Abstract

Pazopanib and sunitinib have similar efficacy, but the safety and quality-of-life profiles favor pazopanib. (Funded by GlaxoSmithKline Pharmaceuticals; COMPARZ ClinicalTrials.gov number, NCT00720941.).

Topics & Keywords

Renal cell carcinoma treatment Renal and related cancers Economic and Financial Impacts of Cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 369, Issue 8, pp. 722-731

DOI: 10.1056/nejmoa1303989

Field-Weighted Citation Impact: 128.28